<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619994</url>
  </required_header>
  <id_info>
    <org_study_id>MDR-END</org_study_id>
    <nct_id>NCT02619994</nct_id>
  </id_info>
  <brief_title>Treatment Shortening of MDR-TB Using Existing and New Drugs</brief_title>
  <acronym>MDR-END</acronym>
  <official_title>Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2, Multicenter, Randomized, Open-label, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dankook University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Tuberculosis Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Institute of Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Medical Center, Seoul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of a 'new treatment regimen including
      delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months
      (investigational arm)' and 'the standard treatment regimen including injectables for 20 to 24
      months (control arm)' for treating quinolone sensitive multidrug-resistant tuberculosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success rate</measure>
    <time_frame>24 months after treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to sputum culture conversion to negative (liquid and solid culture medium)</measure>
    <time_frame>During 6 months of treatment</time_frame>
    <description>From date of randomization until the date of conversion assessed up to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture conversion proportion (liquid culture medium)</measure>
    <time_frame>At 2 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture conversion proportion (liquid culture medium)</measure>
    <time_frame>At six months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.
Intensive phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.
Treatment duration: for at least 20 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.
Delamanid (100 mg bid for the entire treatment period)
Linezolid (600mg/day for 2 months and 300mg/day afterwards until the end of treatment)
Levofloxacin (750 ~1000 mg/day)
Pyrazinamide (1000~ 2000 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delamanid</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Locally-used WHO-approved MDR-TB regimen in Korea</intervention_name>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged from 19 to 85 years

          -  Confirmed Rifampicin resistance

          -  On current TB therapy for ≤14 days at the time of enrollment.

        Exclusion Criteria:

          -  Known any quinolone-resistant MDR-TB patients

          -  Known XDR-TB patients

          -  Patients who are pregnant or who are unwilling to use proper contraceptives at
             childbearing age

          -  Medical history of galactose intolerance, Lapp lactase deficiency, glucose-galactose
             malabsorption

          -  The need for ongoing use of prohibited drugs while on study drugs

          -  History of optic neuropathy or peripheral neuropathy

          -  People with any of the following test results: i.Absolute neutrophil count &lt; 2000
             cells/mL, ii.White blood cell count (WBC) &lt; 3.0 X 103/µL, iii.Hemoglobin &lt; 7.0 g/dL,
             iv.Serum creatinine &gt; 2.0 mg/dL, v.Aspartate aminotransferase (AST or SGOT) &gt;100 IU/L,
             vi.Alanine aminotransferase (ALT or SGPT) &gt;100 IU/L, vii.Total bilirubin &gt; 2.0 mg/dL,
             viii.Albumin &lt; 2.8g/dL, ix.QTcF &gt; 500ms

          -  History of hypersensitivity reaction to the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae-Joon Yim, MD</last_name>
    <phone>+82-2-2072-2059</phone>
    <email>yimjj@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Joon Yim, MD</last_name>
      <phone>+82-2-2072-2059</phone>
      <email>yimjj@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae-Joon Yim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>MDR tuberculosis</keyword>
  <keyword>linezolid</keyword>
  <keyword>delamanid</keyword>
  <keyword>Korea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

